title: Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register.
abstract: BACKGROUND
  The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a prospective, observational cohort designed to assess the long-term safety of biologic and conventional systemic therapies used for adults with moderate-to-severe psoriasis in the U.K. and Republic of Ireland.
  
  
  OBJECTIVE
  To describe the demographics, disease severity and comorbidities of patients with psoriasis on enrolment into BADBIR, and to highlight differences in those commencing biologics compared with those on conventional systemic therapies.
  
  
  METHODS
  Baseline data were collected from 151 dermatology departments in the U.K. and Republic of Ireland. Descriptive analysis was conducted.
  
  
  RESULTS
  As of August 2014, 8399 patients were registered with BADBIR; 5065 (60%) received biologics, of whom 52·8% received adalimumab, 24·6% etanercept, 18·7% ustekinumab and 3·9% infliximab. In the comparator cohort 44·1% received methotrexate, 23·1% ciclosporin, 18·0% acitretin and 7·6% fumaric acid esters. Overall 4897 (58%) were male. Patients on biologics had a higher mean ± SD age and disease duration than patients on conventional systemic therapies (46·3 ± 12·7 vs. 44·3 ± 14·3 years and 23·0 ± 12·6 vs. 19·0 ± 13·4 years, respectively; both P < 0·001). Mean body mass index, Psoriasis Area and Severity Index and Dermatology Life Quality Index scores for patients on biologics were higher than for those on conventional systemic therapies (31·0 ± 7·2 vs. 30·1 ± 7·3 kg m(-2) ; 16·4 ± 8·3 vs. 15·5 ± 7·9 and 17·4 ± 7·5 vs. 15·0 ± 7·1, respectively; all P < 0·001). In total 71% of all patients had comorbidities and 47% had more than one comorbidity. The most frequent comorbidities were obesity (42·1%), hypertension (25·7%), depression (22·1%) and psoriatic arthritis (17·1%).
  
  
  CONCLUSIONS
  BADBIR is an invaluable resource to study the safety and effectiveness of both biologic and conventional systemic therapies. Understanding differences in baseline characteristics between cohorts is crucial in undertaking future pharmacovigilance studies.
authors.affiliation: Centre for Pharmacoepidemiology and Drug Safety, Manchester Pharmacy School, The University of Manchester, Manchester, U.K.
authors.forename: I Y K
authors.initials: IY
authors.lastname: Iskandar
authors.affiliation: Centre for Pharmacoepidemiology and Drug Safety, Manchester Pharmacy School, The University of Manchester, Manchester, U.K.
authors.forename: D M
authors.initials: DM
authors.lastname: Ashcroft
authors.affiliation: Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Barnes Building, Manchester, M6 8HD, U.K.
authors.forename: R B
authors.initials: RB
authors.lastname: Warren
authors.affiliation: Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Barnes Building, Manchester, M6 8HD, U.K.
authors.forename: Z Z N
authors.initials: ZZ
authors.lastname: Yiu
authors.affiliation: Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Barnes Building, Manchester, M6 8HD, U.K.
authors.forename: K
authors.initials: K
authors.lastname: McElhone
authors.affiliation: Arthritis Research U.K. Epidemiology Unit, The University of Manchester, Manchester, U.K.
authors.forename: M
authors.initials: M
authors.lastname: Lunt
authors.affiliation: St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, U.K.
authors.forename: J N W N
authors.initials: JN
authors.lastname: Barker
authors.affiliation: Department of Dermatology, Western Infirmary, Glasgow, U.K.
authors.forename: A D
authors.initials: AD
authors.lastname: Burden
authors.affiliation: Division of Applied Medicine, University of Aberdeen, Foresterhill, Aberdeen, U.K.
authors.forename: A D
authors.initials: AD
authors.lastname: Ormerod
authors.affiliation: Dermatological Sciences, Institute of Cellular Medicine, Medical School, Royal Victoria Infirmary, Newcastle University, Newcastle upon Tyne, U.K.
authors.forename: N J
authors.initials: NJ
authors.lastname: Reynolds
authors.affiliation: St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, U.K.
authors.forename: C H
authors.initials: CH
authors.lastname: Smith
authors.affiliation: Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Barnes Building, Manchester, M6 8HD, U.K.
authors.forename: C E M
authors.initials: CE
authors.lastname: Griffiths
mesh_terms: D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000368:Aged; D001685:Biological Factors / Q000627:therapeutic use; D015897:Comorbidity; D003879:Dermatologic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*; D011788:Quality of Life; D012042:Registries; D006113:United Kingdom / Q000453:epidemiology; D055815:Young Adult
chemical_list: D001685:Biological Factors; D003879:Dermatologic Agents